characteristics.text: ERC000011
characteristics.characteristic: ENA-CHECKLIST
characteristics.text: 2020-01-03T15:59:08Z
characteristics.characteristic: ENA-FIRST-PUBLIC
characteristics.text: 2018-03-13T12:24:05Z
characteristics.characteristic: ENA-LAST-UPDATE
characteristics.text: SAMEA104685205
characteristics.characteristic: External Id
characteristics.text: Quadram Institute Bioscience
characteristics.characteristic: INSDC center name
characteristics.text: 2020-01-03T15:59:08Z
characteristics.characteristic: INSDC first public
characteristics.text: 2018-03-13T12:24:05Z
characteristics.characteristic: INSDC last update
characteristics.text: public
characteristics.characteristic: INSDC status
characteristics.text: ERS2286588
characteristics.characteristic: SRA accession
characteristics.text: E-MTAB-6525:LIB28033
characteristics.characteristic: Submitter Id
characteristics.text: 59
characteristics.unit: year
characteristics.characteristic: age
characteristics.text: body mass index at start 27.5
characteristics.unit: kilogram per square meter
characteristics.characteristic: body mass index
characteristics.text: ArrayExpress
characteristics.ontologyTerms: http://www.ebi.ac.uk/efo/EFO_0009737
characteristics.characteristic: broker name
characteristics.text: prostate specific antigen measurement 5.1
characteristics.unit: nanogram per milliliter
characteristics.characteristic: clinical information
characteristics.text: human
characteristics.ontologyTerms: http://purl.obolibrary.org/obo/NCBITaxon_9606
characteristics.characteristic: common name
characteristics.text: Protocols: Forty-nine men with a clinical diagnosis of low- or intermediate-risk organ-confined prostate cancer underwent two transperineal template biopsy procedures at 12-month intervals. All patients had an American Society of Anaesthesiologists (ASA) co-morbidity score of 1 or 2, which reflects the health status of men eligible for active surveillance. Of the 25-35 cores obtained each at T0 and T12, three were reserved for next generation sequencing (NGS), three were used for targeted and non-targeted metabolite analyses, two were snap frozen and the remainder underwent routine histopathological examination. ESCAPE study design. The ESCAPE study involved the recruitment of 49 men with of low- or intermediate-risk organ-confined prostate cancer underwent two transperineal template biopsy procedures at 12-month intervals. The protocol was approved by the Quadram Institute Bioscience Human Research Governance Committee and subsequently by the National Research Ethics Service (NRES) East of England - Cambridge South Research Ethics Committee (REC ref: 13/EE/0110). ESCAPE has been adopted on the National Institute for Health Research Clinical Research Network (NIHR) Clinical Research Network (CRN) Portfolio in May 2013 (Study ID: 14482). The trial has been registered on ClinicalTrials.gov (NCT01950143), (ii) International Clinical Trials Registry Platform (ISRCTN40496794), and (iii) Clinical Trials database Cancer Research UK (http://www.cancerresearchuk.org/cancer-help/trials/a-trial-looking-effect-sulforaphaneprostate-cancer-escape. Immediately prior to the study, the volunteers completed a comprehensive seven-day diet diary to assess their habitual diet. During the 12-month interval, the volunteers consumed their habitual diet supplemented with one 300 ml portion of a broccoli-based soup per week. The soups were otherwise identical but were manufactured from one of three broccoli Myb28 genotypes, delivering a mean ± standard deviation for standard broccoli soup of 8.4 ± 2.8, beneforte soup of 280 ± 8.8 and beneforte extra soup of 452 ± 10.6 µmoles glucoraphanin per 300 ml portion. Further diet diaries were completed at six and twelve months. Diet data from both habitual diet and the additional soups were integrated and analysed through DietPlan6 combined with additional data on chemical composition of cruciferous and alliaceous vegetables obtained from analyses of vegetables purchased in the retail outlets in the localities of the volunteers. Disease staging refers to WHO grade for prostate carcinoma. Two cores per patient weighing between 3 and 10 mg in total were homogenised with a QIAGEN TissueRuptor before total RNA was extracted with the QIAGEN RNeasy Mini kit. The resulting RNA was quality checked with an Agilent Bioanalyzer and samples with RIN values higher than 7 were further processed. Samples were subjected to ribodepletion with the Ribo-Zero Magnetic Gold rRNA Removal Kit (Illumina). Libraries were constructed with the Illumina barcoded TruSeq kit.
characteristics.characteristic: description
characteristics.text: prostate carcinoma
characteristics.ontologyTerms: http://www.ebi.ac.uk/efo/EFO_0001663
characteristics.characteristic: disease
characteristics.text: 1
characteristics.characteristic: disease staging
characteristics.text: LIB28033
characteristics.characteristic: individual
characteristics.text: Homo sapiens
characteristics.characteristic: organism
characteristics.text: Homo sapiens
characteristics.ontologyTerms: http://purl.obolibrary.org/obo/NCBITaxon_9606
characteristics.characteristic: organism
characteristics.text: prostate
characteristics.ontologyTerms: http://purl.obolibrary.org/obo/UBERON_0002367
characteristics.characteristic: organism part
characteristics.text: Homo sapiens
characteristics.characteristic: scientific_name
characteristics.text: male
characteristics.ontologyTerms: http://purl.obolibrary.org/obo/PATO_0000384
characteristics.characteristic: sex
characteristics.text: ESC032-T0
characteristics.characteristic: studycode
characteristics.text: LIB28033
characteristics.characteristic: title